Our key medical staff has come to us from a wide range of prominent institutions:

Harvard Medical School
Harvard University
UCLA Medical Center Blood Bank
UCLA Tissue Typing Laboratory
UCLA Stem Cell Laboratory
UCLA Clinical Laboratory
UCLA/National Institute of Health COBLT Cord Blood Bank
City of Hope National Medical Center
American Red Cross Blood Center
Ohio State University

Ram Bhat, Ph.D.
Chief Scientific Officer

Dr. Ram Bhat joined StemCyte in late 2005 as the Chief Scientific Officer. His previous professional tenure included two years of teaching at the University of Maryland at College Park and nearly 30 years at Johnson & Johnson where his assignments ranged from Manager of Basic & Applied Research at Baby Products Company to Director of Research at Vistakon, Director of Technology Transfer in Japan, Corporate Director at Corporate Office of Science & Technology and Vice President & Executive Director at Vision Care. His career is also highlighted by a one year White House (Executive Branch) Fellowship at the Office of Science & Technology Policy during the Clinton Administration. Dr. Bhat’s educational background consists of B. S. degrees in Physics, Mathematics and Engineering from India, M. S. and Ph. D. degrees in Polymer Science (Physics) from N. C. State University, and a Post-Doctoral Fellowship at the National Bureau of Standards.

David A. Carmel, MBA
Vice President, Business Development

Prior to joining StemCyte, David Carmel was a manager in Pfizer’s Planning & Business Development group and worked in marketing at Independence Technology, a Johnson & Johnson Company. In the 2004 election cycle, he worked on the California Stem Cell and Cures Initiative (Prop 71), a $3 billion bond issue passed by 59% of Californians. He is a former White House Fellow to the Secretary of the Treasury in Washington and a co-founder of Jumpstart for Young Children. He earned an MBA from the Stanford Graduate School of Business and a BA from Harvard College. He is a Henry Crown Fellow of the Aspen Institute and a board member of the New York Stem Cell Foundation, the East Harlem School, and the New York State Spinal Cord Injury Research Board.

Henry Chase, MS, CPA
Vice President, Finance

Henry Chase has a 30-year career in financial management including broad experience in strategic and financial analysis, planning and reporting, IPO’s, treasury, cash management, raising capital and mergers and acquisitions in the technology, bio-tech, manufacturing, consumer products and distribution sectors and joined StemCyte in 2005. He is a Partner at Tatum, which is the nation’s largest and fastest-growing executive services firm, helping companies in transition to accelerate business success and create more value. Mr. Chase earned his B. S. in Economics at California Polytechnic State University and M. S. in Finance at San Diego State University.

Robert Chow, M.D., A.M.
Vice Chairman & Founder
Global Medical Director, StemCyte, Inc.

Dr. Chow is the Founder of StemCyte and successfully raised several rounds of investment as its founding Chairman. He currently serves as StemCyte’s Vice-Chairman. A physician-scientist-entrepreneur, he founded three other companies. As an ex officio member of the Executive Committee and Cord Blood Committee of the National Marrow Donor Program, Dr. Chow serves or has served as the Chairman or Board Director for numerous companies. Inventor of StemCyte cord blood technologies, he has several patents pending or allowed. Dr. Chow earned his M. D. and A. M. at Harvard Medical School, followed by Residency and Fellowship in Laboratory Medicine at UCLA.

Robert Dickey, IV
Senior Vice President & Chief Financial Officer

Rob Dickey has more than 25 years’ experience in entrepreneurial management and in investment banking. Mr. Dickey has been involved in the building and management of high growth companies, in private and public market fundraising, IPO’s and mergers and acquisitions and in structuring and negotiating academic collaborations and licensing agreements. Before StemCyte, he was CFO at Locus Pharmaceuticals, Inc. where he raised over $40 million in debt and equity financing and from partnering revenues. Previously, Mr. Dickey was President, CEO and CFO of Protarga, Inc., where he raised more than $55 million, filed a registration statement to take Protarga public and then sold the company to Daiichi Sankyo, Co., Ltd. He began his career on Wall Street spending 13 years at Lehman Brothers in general corporate finance and in the M&A department and then four years as a Managing Director at Legg Mason Wood Walker. Mr. Dickey holds an MBA from The Wharton School, University of Pennsylvania, and a B.A. from Princeton University.

Kenneth J. Giacin, MBA, MS
Chairman & Chief Executive Officer

Ken Giacin joined StemCyte in 2003, bringing world-class leadership to guide the company's growth through new investments and technological affiliations. Prior to joining StemCyte, he held positions as Senior Vice President of Independence Technology at Johnson & Johnson, Corporate Vice President at Church & Dwight/Arm & Hammer, and was Vice President of Johnson & Johnson Baby Products Co. Mr. Giacin holds both an M.B.A. and an M.S. degree from Rutgers University. Prior to his career in business, he served as a carrier pilot and officer in the U.S. Navy.

Charles Lu
Chief Executive Officer, StemCyte Taiwan

Mr. Lu has more than 13 years of experience in pharmaceutical business development and medical devices. Prior to joining StemCyte, Mr. Lu was the Chairman and General Manager of You An, a drugstore group in Taiwan, which he developed from three stores to 50 stores within three years. Previously, Mr. Lu was a senior marketing executive with Johnson & Johnson’s Janssen Pharmaceutical unit. Mr. Lu received his M.B.A. from the University of Hartford Business School in Paris.

Professor Lawrence D. Petz, M.D.
Chairman, Medical Advisory Board
Chief Medical Officer and Co-Medical Director, StemCyte International Cord Blood Center(US)

Dr. Petz joined StemCyte after serving as Director of Transfusion Medicine and Professor of Pathology & Laboratory Medicine at UCLA Medical Center. Prior to UCLA, Dr. Petz was Chairman of the Division of Medicine, Section Head of Hematology, and Director of the Department of Clinical and Experimental Immunology at the City of Hope National Medical Center. Dr. Petz is the author or editor of several well-known, authoritative textbooks, including the first bone marrow stem cell transplant textbook, Clinical Bone Marrow Transplantation (1983), all three editions of the widely used blood bank textbook, Clinical Practice of Transfusion Medicine, and the co-author of Immune Hemolytic Anemias, now in its second edition. As a pre-eminent authority in transfusion medicine and transplantation, Dr. Petz has authored and edited hundreds of publications, book chapters, and reviews, and has published in New England Journal of Medicine, JAMA, Lancet, Annals of Internal Medicine, Transfusion Medicine, Transfusion, Transplantation, Bone Marrow Transplant, Journal of Clinical Investigation, Postgraduate Medicine, Transfusion Medicine, Medicine, Journal of Immunology, Blood, British Journal of Hematology, to name just a few. Dr. Petz is a diplomate in internal medicine and subspecialty board diplomate in hematology. He has chaired or served on over twenty transfusion medicine and hematology committees, and has received some of the highest honors in transfusion medicine, including the Emily Cooley Award, the and Morten Grove-Rasmussen Memorial Award and the Tibor Greenwalt Memorial Award and Lectureship from the American Association of Blood Banks (AABB); the Transfusion Medicine Academic Award from National Heart, Lung, and Blood Institute; and the Owen Thomas Award from the California Blood Bank Society. Dr. Petz chairs StemCyte's prestigious Medical Advisory Board.